InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,907.86
(
0.99%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oldchemist4

Send PM Follow Ignore
Followers 2
Posts 198
Boards Moderated 0
Alias Born 12/16/2012

oldchemist4

Re: jaybe post# 33958

Monday, 09/09/2013 11:42:48 AM

Monday, September 09, 2013 11:42:48 AM

Post# of 80490
Thanks! A massive composition-of-matter & synthesis application with priority date in April/May 2011. Says a great deal about the quality of the ARIAD team.

Doesn't specifically mention glioblastoma (I may have missed it) but the opening sentence in the summary (which is what is read first in a patent search) is telling:

"It has been unexpectedly discovered that certain targeted TKI's cross the blood brain barrier....."

I know I am getting really boring with this, but these "off target" properties are going to be the real drivers of valuation.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up